CN-117800889-B - New compound, preparation method thereof and application of new compound in treating influenza

Abstract

The invention discloses a novel compound, a preparation method thereof and application thereof in treating influenza, wherein the structural formula of the compound is The compound can inhibit neuraminidase activity and can be used for developing medicaments for treating influenza.

Inventors

• LI NA

Assignees

• 潍坊科技学院

Dates

Publication Date

20260512

Application Date

20231222

Claims (4)

1. 1. A novel compound is characterized by comprising the following chemical structure: 。
2. 2. a process for preparing the novel compounds as claimed in claim 1, comprising the following steps: (1) Percolating herba Lobeliae chinensis with extraction solvent, concentrating the extractive solution to obtain crude extract; (2) Dispersing the crude extract in water, extracting with ethyl acetate, collecting ethyl acetate extract, concentrating to obtain ethyl acetate extract; (3) Extracting the extractum with ethyl acetate, separating with silica gel column, eluting with ethyl acetate-ethanol in the volume ratio of 100 to 1 for 10 column volumes, discarding the eluent, eluting with ethyl acetate-ethanol in the volume ratio of 50 to 1 for 10 column volumes, discarding the eluent, eluting with ethyl acetate-ethanol in the volume ratio of 25 to 1 for 10 column volumes, discarding the eluent, eluting with ethyl acetate-ethanol in the volume ratio of 12.5 to 1 for 10 column volumes, collecting the eluent, and concentrating to obtain extractum; (4) And (3) further separating the extract obtained in the step (3) through Sephadex LH-20 gel, tracking and monitoring by using thin layer chromatography with methanol as a mobile phase, collecting the target compound eluent, concentrating, and repeating the step until the purity of the obtained compound reaches 98% through high performance liquid chromatography detection.
3. 3. A process for preparing a novel compound according to claim 2, wherein the extraction solvent is an absolute ethanol solution.
4. 4. Use of a novel compound according to claim 1 for the manufacture of a medicament for the inhibition of neuraminidase for the treatment of influenza.

Description

New compound, preparation method thereof and application of new compound in treating influenza Technical Field The invention belongs to the technical field of medicines, and particularly relates to a novel compound, a preparation method thereof and application of the novel compound in treating influenza. Background Influenza (influenza for short) is an acute respiratory tract infection caused by influenza virus, and is also a disease with strong infectivity and high transmission speed. It is transmitted mainly by droplets in the air, by person-to-person contact or by contact with contaminated objects. Typical clinical symptoms are acute high fever, general pain, significant debilitation and mild respiratory symptoms. In autumn and winter, the complications and death caused by the season are serious. Influenza viruses can be classified into three types of A (A), B (B) and C (C), and the A type viruses often have antigen mutation, are large in infectivity and rapid in transmission, and are extremely easy to generate pandemic. Infants, the elderly and patients with heart and lung basic diseases are easy to cause death due to serious complications such as pneumonia. The current anti-influenza drugs are mainly divided into M2 ion channel inhibitors, RNA polymerase inhibitors, hemagglutinin HA inhibitors, cap dependent endonuclease inhibitors and neuraminidase inhibitors according to different action mechanisms. Neuraminidase, also known as sialidase, is a glycoprotein distributed on the envelope of influenza virus, and can catalyze sialic acid hydrolysis to assist mature influenza virus to separate from host cells and infect new cells, and plays an important role in the transmission process of influenza virus. The neuraminidase inhibitor is mainly used for blocking the replication and release of viruses by inhibiting the activity of neuraminidase on the surface of respiratory viruses, achieves the effect of resisting influenza viruses, and is the most widely used medicament for treating and preventing influenza at present. Herba Lobeliae chinensis is dried whole herb of Lour of Lobelia chinensis Lobelia chinensis belonging to the family Campanulaceae. Has the effects of clearing heat and detoxicating, promoting urination and reducing swelling, and can be used for treating carbuncle, furuncle, snake and insect bite, swelling edema, eczema and wet sore clinically. Modern pharmacological studies have shown that lobelia has anti-influenza virus activity, but its active ingredients are not quite clear. Because influenza viruses are very variable, drug-resistant viruses are rapidly appeared along with the wide use of neuraminidase inhibitors, so research discovers that anti-influenza drugs with novel structures have very important significance, and searching active ingredients from natural products with anti-influenza virus effects is an important way for research and development of new drugs. Disclosure of Invention The invention aims to provide a novel compound capable of inhibiting neuraminidase activity, and also provides a preparation method thereof, and the novel compound is obtained by performing systematic separation on whole herb of Chinese lobelia. The chemical structure of the novel compound is as follows: The preparation method of the novel compound comprises the following steps: (1) Percolating herba Lobeliae chinensis with absolute ethanol, and concentrating the extractive solution to obtain crude extract; (2) Dispersing the crude extract in water, extracting with ethyl acetate, collecting ethyl acetate extract, concentrating to obtain ethyl acetate extract; (3) Extracting the extractum with ethyl acetate, separating with silica gel column, eluting with 10 column volumes with ethyl acetate-ethanol (100:1) in volume ratio, discarding the eluent, eluting with 10 column volumes with ethyl acetate-ethanol (50:1) in volume ratio, discarding the eluent, eluting with 10 column volumes with ethyl acetate-ethanol (25:1) in volume ratio, discarding the eluent, eluting with 10 column volumes with ethyl acetate-ethanol (12.5:1) in volume ratio, collecting the eluent, and concentrating to obtain extractum; (4) And (3) further separating the extract obtained in the step (3) through Sephadex LH-20 gel, tracking and monitoring by using thin layer chromatography with methanol as a mobile phase, collecting the target compound eluent, and repeating the step until the purity of the obtained compound reaches 98% through high performance liquid chromatography detection. The novel compounds of the invention are useful for the preparation of neuraminidase inhibitors, developed as medicaments for the treatment of influenza. 1. Structural confirmation of the Compounds described in the present invention As shown in FIGS. 1 to 4, colorless needle crystals (methanol) were dissolved in methanol. The molecular ion peak of m/z 378.1553[ M+H ] + (calculated value 378.1553) is obtained by high-resolution mass spectrum at the melting poin